Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diflucan Generics Launch Following Expiration Of Pfizer Exclusivity

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approves numerous ANDAs for tablet, oral suspension and injectable forms of the antifungal upon expiration of Diflucan's six-month pediatric extension. Pfizer is marketing its own generic through its Greenstone subsidiary.

You may also be interested in...



Pfizer To Spring Forward With Eraxis Launch

Anidulafungin is approved for treatment of esophageal candidiasis and candidemia.

Pfizer To Spring Forward With Eraxis Launch

Anidulafungin is approved for treatment of esophageal candidiasis and candidemia.

Pfizer Vfend Approved For Candidemia

Supplemental indication is based on trial showing voriconazole was as effective as a regimen of amphotericin B followed by fluconazole. Pfizer may try to differentiate the product based on adverse event profile.

Related Content

Topics

UsernamePublicRestriction

Register

PS060170

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel